Kazia Therapeutics Limited. (KZIA)

Every figure this model derived for KZIA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2025-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2017-06-30
cash 69,459,980 CashAndCashEquivalents 2025-12-31
current assets 69,986,017 CurrentAssets 2025-12-31
current liabilities 24,373,328 CurrentLiabilities 2025-12-31
equity 46,467,039 Equity 2025-12-31
interest expense 0 InterestPaidClassifiedAsOperatingActivities 2024-12-31
ocf -13,278,000 CashFlowsFromUsedInOperatingActivities 2025-06-30
revenue 42,000 Revenue 2025-06-30
sbc 653,194,000 ExpenseFromSharebasedPaymentTransactionsWithEmployees 2025-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up KZIA on one particular measure came for.

RatioValue
current ratio2.87
current ratio reported2.87
dilution pct107.91
revenue growth-98.18
revenue growth per share-99.12

What to be careful about

What this model itself distrusts about KZIA's figures. Written by the derivation as it ran, not added afterwards.